Development, validation and regulatory acceptance of improved purification and simplified quality control of [13N] Ammonia

Daniel L. Yokell, Peter A. Rice, Ramesh Neelamegam, Georges El Fakhri

Research output: Contribution to journalArticlepeer-review

Abstract

Background: [13N]Ammonia is a cyclotron produced myocardial perfusion imaging agent. With the development of high-yielding [13N]ammonia cyclotron targets using a solution of 5 mM ethanol in water, there was a need to develop and validate an automated purification and formulation system for [13N]ammonia to be in a physiological compatible formulation of 0.9% sodium chloride since there is no widely available commercial system at this time. Due to its short half-life of 10 min, FDA and USP regulations allow [13N]ammonia to be tested in quality control (QC) sub-batches with limited quality control testing performed on the sub-batches for patient use. The current EP and the original USP method for the determination of the radiochemical purity and identity of [13N]ammonia depended on an HPLC method using a conductivity detector and a solvent free of other salts. This HPLC method created issues in a modern cGMP high volume PET manufacturing facility where the HPLC is used with salt containing mobile phase buffers for quality control analysis of other PET radiopharmaceuticals. Flushing of the HPLC system of residual salt buffers which may interfere with the [13N]ammonia assay can take several hours of instrument time. Since there are no mass limits on [13N]ammonia, a simplified TLC assay to determine radiochemical identity and purity could be developed to simplify and streamline QC. Results: We have developed and validated a streamlined automated synthesis for [13N]ammonia which provides the drug product in 8 mL of 0.9% sodium chloride for injection. A novel radio-TLC method was developed and validated to demonstrate feasibility to quantitate [13N]ammonia and separate it from all known radiochemical impurities. Conclusions: The process for automated synthesis of [13N]ammonia simplifies and automates the purification and formulation of [13N]ammonia in a cGMP compliant manner needed for high-throughput manufacture of [13N]ammonia. The novel radio-TLC method has simplified [13N]ammonia quality control (QC) and now enables it to be tested using the same QC equipment as [18F]fludeoxyglucose (FDA/USP recognized name for 2-[18F]fluoro-2-deoxy-D-glucose). Both the streamlined automated synthesis of [13N]ammonia and the novel radio-TLC method have been accepted and approved by the US Food and Drug Administration (FDA) for the cGMP manufacture of [13N]ammonia.

Original languageEnglish (US)
Article number11
JournalEJNMMI Radiopharmacy and Chemistry
Volume5
Issue number1
DOIs
StatePublished - Dec 1 2020
Externally publishedYes

Keywords

  • Automated radiochemistry
  • Cardiac PET
  • PET radiopharmaceutical quality control
  • Regulatory
  • [N]Ammonia
  • [N]NH
  • cGMP PET drug manufacturing

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Analytical Chemistry
  • Pharmacology (medical)
  • Pharmacology

Fingerprint

Dive into the research topics of 'Development, validation and regulatory acceptance of improved purification and simplified quality control of [13N] Ammonia'. Together they form a unique fingerprint.

Cite this